AssetMark Inc’s Meridian Bioscience Inc VIVO Stock Holding History

AssetMark Inc’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-72	Closed	-$2.39K	–	1730
2022 Q4	$2.39K	Hold	72	–	–	﹤0.01%	1424
2022 Q3	$2K	Buy	72 +2	+3%	+$65	﹤0.01%	1416
2022 Q2	$2K	Hold	70	–	–	﹤0.01%	1398
2022 Q1	$2K	Buy	70 +9	+15%	+$214	﹤0.01%	1456
2021 Q4	$1K	Hold	61	–	–	﹤0.01%	1492
2021 Q3	$1K	Sell	61 -27,126	-100%	-$541K	﹤0.01%	1374
2021 Q2	$603K	Buy	27,187 +2,931	+12%	+$62.2K	﹤0.01%	434
2021 Q1	$637K	Buy	+24,256	New	+$577K	﹤0.01%	417
2018 Q1	–	Sell	-62	Closed	-$1K	–	2112
2017 Q4	$1K	Buy	+62	New	+$908	﹤0.01%	1770

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

AssetMark Inc's VIVO Position: Q1 2023 in Review

AssetMark Inc sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 72 shares — an estimated $2.39K sold.

AssetMark Inc first reported a position in VIVO in Q4 2017 and held it in 9 quarters. The position peaked at $637K in Q1 2021. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

AssetMark Inc reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
AssetMark Inc sold 72 Meridian Bioscience Inc shares in Q1 2023, an estimated $2.39K.
AssetMark Inc first reported a position in Meridian Bioscience Inc in Q4 2017 and held it in 9 quarters.
AssetMark Inc's Meridian Bioscience Inc position peaked at $637K in Q1 2021.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on AssetMark Inc's 13F filing for Q1 2023, filed 5 May 2023.